Published in Cancer Res on December 01, 2006
The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Res Treat (2009) 1.29
Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. Bioorg Med Chem (2007) 1.20
Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem (2007) 1.07
Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer (2007) 1.03
MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Breast Cancer Res (2015) 0.93
First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines. Oncotarget (2014) 0.88
MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours. Br J Cancer (2008) 0.86
Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: Luminal phenotype and RARα expression. EMBO Mol Med (2015) 0.82
Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics. Curr Top Med Chem (2013) 0.82
Epigenetic targeting in breast cancer: therapeutic impact and future direction. Drug News Perspect (2009) 0.80
VN/14-1 induces ER stress and autophagy in HP-LTLC human breast cancer cells and has excellent oral pharmacokinetic profile in female Sprague Dawley rats. Eur J Pharmacol (2014) 0.79
Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines. Oncotarget (2015) 0.78
Murine toxicology and pharmacokinetics evaluation of retinoic acid metabolism blocking agent (RAMBA), VN/12-1. Cancer Chemother Pharmacol (2012) 0.78
Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitors. Clin Cancer Res (2011) 0.78
Anti-tumor effects of a novel retinoic acid metabolism blocking agent VN/14-1 in the N-methyl-N-nitrosourea-induced rat mammary carcinoma model and its effects on the uterus. Breast Cancer Res Treat (2011) 0.76
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res (2009) 6.15
Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell (2006) 3.16
Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids (2006) 1.89
Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res (2005) 1.84
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem (2005) 1.80
CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol (2010) 1.70
Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther (2008) 1.59
Stopping treatment can reverse acquired resistance to letrozole. Cancer Res (2008) 1.39
A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. J Med Chem (2005) 1.33
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res (2005) 1.23
Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells. J Biol Chem (2011) 1.21
Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. Bioorg Med Chem (2007) 1.20
The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate (2004) 1.15
Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. Breast Cancer Res Treat (2010) 1.14
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. J Med Chem (2013) 1.11
Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res (2011) 1.09
Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem (2007) 1.07
Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent. Bioorg Med Chem (2008) 1.03
Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. J Med Chem (2015) 1.02
Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Mol Cancer Ther (2008) 0.99
Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist (2008) 0.99
17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Mol Cancer Ther (2008) 0.99
Autophagy inhibition synergistically enhances anticancer efficacy of RAMBA, VN/12-1 in SKBR-3 cells, and tumor xenografts. Mol Cancer Ther (2012) 0.92
First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines. Oncotarget (2014) 0.88
Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. Clin Cancer Res (2004) 0.88
Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy. J Med Chem (2003) 0.87
Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents. Cancer Chemother Pharmacol (2007) 0.87
Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy. Drug Metab Dispos (2010) 0.82
Synthesis of novel C17 steroidal carbamates. Studies on CYP17 action, androgen receptor binding and function, and prostate cancer cell growth. Steroids (2008) 0.82
Aromatase inhibitors and xenograft studies. Steroids (2011) 0.82
Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments. Future Med Chem (2010) 0.81
Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model. J Steroid Biochem Mol Biol (2004) 0.81
First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents. Bioorg Med Chem (2007) 0.81
A new simple and high-yield synthesis of 5α-dihydrotestosterone (DHT), a potent androgen receptor agonist. Steroids (2012) 0.80
New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer. Prostate Cancer (2011) 0.79
Murine toxicology and pharmacokinetics evaluation of retinoic acid metabolism blocking agent (RAMBA), VN/12-1. Cancer Chemother Pharmacol (2012) 0.78
Upregulation of AIB1, aromatase and ERα provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival. Horm Mol Biol Clin Investig (2011) 0.78
Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors. Steroids (2007) 0.77
Anti-tumor effects of a novel retinoic acid metabolism blocking agent VN/14-1 in the N-methyl-N-nitrosourea-induced rat mammary carcinoma model and its effects on the uterus. Breast Cancer Res Treat (2011) 0.76
Novel P450(17alpha) inhibitors: 17-(2'-oxazolyl)- and 17-(2'-thiazolyl)-androstene derivatives. Steroids (2003) 0.76
First chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): identification of novel RAMBA scaffolds. Eur J Med Chem (2011) 0.75
Extending aromatase inhibitor sensitivity in hormone resistant breast cancer. Horm Mol Biol Clin Investig (2011) 0.75
Upregulation of AIB1, aromatase and ERα provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival. Horm Mol Biol Clin Investig (2010) 0.75
Pharmacokinetics of novel inhibitors of androgen synthesis after intravenous administration in mice. Cancer Chemother Pharmacol (2003) 0.75
Targeting of protein translation as a new treatment paradigm for prostate cancer. Curr Opin Oncol (2017) 0.75